Thomas J. McClelland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas J. McClelland has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
John Prowle
William Harvey Research Institute, Barts and The London School of Medicine & Dentistry Queen Mary University of London London UK
3 shared publicationsZudin Puthucheary
William Harvey Research Institute, Barts and The London School of Medicine & Dentistry Queen Mary University of London London UK
3 shared publications- Adam Jonathan Boulton
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
2 shared publications - Luke Flower
Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK
2 shared publications - Mandeep Phull
Department of Critical Care, Queens Hospital, Barking Havering and Redbridge University Hospitals NHS Trust, London, UK; Willam Harvey Research Institute, Queen Mary University London, London, UK
2 shared publications Rupert Pearse
William Harvey Research Institute, Barts and The London School of Medicine & Dentistry Queen Mary University of London London UK
2 shared publications
Latest Publications
- 7 August 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (4) , 1269-1270
Identification of difficult airways in critical care units (ID-ACCT). Response to Br J Anaesth 2026; 137: 309–10
- 7 August 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (4) , 1269-1270
Identification of difficult airways in critical care units (ID-ACCT). Response to Br J Anaesth 2026; 137: 309–10
- 19 December 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (2) , 705-715
Identification of difficult airways in critical care units (ID-ACCT): a multicentre, survey-based prospective observational study
- 19 December 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (2) , 705-715
Identification of difficult airways in critical care units (ID-ACCT): a multicentre, survey-based prospective observational study
- Open Access
- 28 February 2024
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 48 (4) , 389-405
Creatine supplementation for optimization of physical function in the patient at risk of functional disability: A systematic review and meta‐analysis
Background: The efficacy of creatine replacement through supplementation for the optimization of physical function in the population at risk of functional disability is unclear.Methods: We conducted a systematic literature search of MEDLINE, EMBASE, the Cochrane Library, and CINAHL from inception to November 2022. Studies included were randomized controlled trials (RCTs) comparing creatine supplementation with placebos in older adults and adults with chronic disease. The primary outcome was physical function measured by the sit‐to‐stand test after pooling data using random‐effects modeling. We also performed a Bayesian meta‐analysis to describe the treatment effect in probability terms. Secondary outcomes included other measures of physical function, muscle function, and body composition. The risk of bias was assessed using the Cochrane risk‐of‐bias tool.Results: We identified 33 RCTs, comprising 1076 participants. From six trials reporting the primary outcome, the pooled standardized mean difference (SMD) was 0.51 (95% confidence interval [CI]: 0.01–1.00; I2 = 62%; P = 0.04); using weakly informative priors, the posterior probability that creatine supplementation improves physical function was 66.7%. Upper‐body muscle strength (SMD: 0.25; 95% CI: 0.06–0.44; I2 = 0%; P = 0.01), handgrip strength (SMD 0.23; 95% CI: 0.01–0.45; I2 = 0%; P = 0.04), and lean tissue mass (MD 1.08 kg; 95% CI: 0.77–1.38; I2 = 26%; P < 0.01) improved with creatine supplementation. The quality of evidence for all outcomes was low or very low because of a high risk of bias.Conclusion: Creatine supplementation improves sit‐to‐stand performance, muscle function, and lean tissue mass. It is crucial to conduct high‐quality prospective RCTs to confirm these hypotheses (PROSPERO number, CRD42023354929).
- 28 February 2024
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 48 (4) , 389-405
Open AccessCreatine supplementation for optimization of physical function in the patient at risk of functional disability: A systematic review and meta‐analysis
Background: The efficacy of creatine replacement through supplementation for the optimization of physical function in the population at risk of functional disability is unclear.Methods: We conducted a systematic literature search of MEDLINE, EMBASE, the Cochrane Library, and CINAHL from inception to November 2022. Studies included were randomized controlled trials (RCTs) comparing creatine supplementation with placebos in older adults and adults with chronic disease. The primary outcome was physical function measured by the sit‐to‐stand test after pooling data using random‐effects modeling. We also performed a Bayesian meta‐analysis to describe the treatment effect in probability terms. Secondary outcomes included other measures of physical function, muscle function, and body composition. The risk of bias was assessed using the Cochrane risk‐of‐bias tool.Results: We identified 33 RCTs, comprising 1076 participants. From six trials reporting the primary outcome, the pooled standardized mean difference (SMD) was 0.51 (95% confidence interval [CI]: 0.01–1.00; I2 = 62%; P = 0.04); using weakly informative priors, the posterior probability that creatine supplementation improves physical function was 66.7%. Upper‐body muscle strength (SMD: 0.25; 95% CI: 0.06–0.44; I2 = 0%; P = 0.01), handgrip strength (SMD 0.23; 95% CI: 0.01–0.45; I2 = 0%; P = 0.04), and lean tissue mass (MD 1.08 kg; 95% CI: 0.77–1.38; I2 = 26%; P < 0.01) improved with creatine supplementation. The quality of evidence for all outcomes was low or very low because of a high risk of bias.Conclusion: Creatine supplementation improves sit‐to‐stand performance, muscle function, and lean tissue mass. It is crucial to conduct high‐quality prospective RCTs to confirm these hypotheses (PROSPERO number, CRD42023354929).
- Open Access
- 22 February 2023
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 47 (4) , 459-475
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review
Background: Skeletal muscle wasting is a determinant of physical disability in survivors of critical illness. Intramuscular bioenergetic failure, altered substrate metabolim, and inflammation are likely underpinning mechanisms. We examined the effect of pioglitazone, a peroxisome proliferator–activated receptor γ agonist, on muscle‐related outcomes in adults.Methods: We included randomized controlled trials in which pioglitazone was administered (no dose/dosage restrictions) and muscle‐related outcomes were reported. We searched MEDLINE, CENTRAL, EMBASE, CINAHL, and trial registries. Risk of bias was assessed using RoB 2. Primary outcomes were physical function and symptoms, muscle mass and function, or body composition and muscular compositional change. Secondary outcomes included muscle insulin sensitivity, mitochondrial effects, and intramuscular inflammation.Results: Fourteen studies over 19 publications (n = 474 patients) were included. Lean body mass was unaffected in three studies (n = 126) and increased by 1.8–1.92 kg in two studies (P = 0.02 and 0.003, respectively; n = 48). Pioglitazone was associated with increased peripheral insulin sensitivity (+23%–72%, standardized mean difference of 0.97 from trial start point to end point [95% CI, 0.36–1.58; n = 213]). Treatment reduced intramuscular tumor necrosis factor‐α (TNF‐α) levels (−30%; P = 0.02; n = 29), with mixed effects on serum TNF‐α and intramyocellular lipid concentrations. Treatment increased intramuscular markers of adenosine triphosphate (ATP) biosynthesis (ATP5A [+33%, P ≤ 0.05], ETFA [+60%, P ≤ 0.05], and CX6B1 [+ 33%, P = 0.01] [n = 24]), PGC1α and PGC1β messenger RNA expression (P < 0.05; n = 26), and AMPK phosphorylation (+38%, P < 0.05; n = 26). These data have low‐quality evidence profiles owing to risk of bias.Conclusions: Pioglitazone therapy increases skeletal muscle insulin sensitivity and can decrease intramuscular inflammation.
- 22 February 2023
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 47 (4) , 459-475
Open AccessCan pioglitazone be used for optimization of nutrition in critical illness? A systematic review
Background: Skeletal muscle wasting is a determinant of physical disability in survivors of critical illness. Intramuscular bioenergetic failure, altered substrate metabolim, and inflammation are likely underpinning mechanisms. We examined the effect of pioglitazone, a peroxisome proliferator–activated receptor γ agonist, on muscle‐related outcomes in adults.Methods: We included randomized controlled trials in which pioglitazone was administered (no dose/dosage restrictions) and muscle‐related outcomes were reported. We searched MEDLINE, CENTRAL, EMBASE, CINAHL, and trial registries. Risk of bias was assessed using RoB 2. Primary outcomes were physical function and symptoms, muscle mass and function, or body composition and muscular compositional change. Secondary outcomes included muscle insulin sensitivity, mitochondrial effects, and intramuscular inflammation.Results: Fourteen studies over 19 publications (n = 474 patients) were included. Lean body mass was unaffected in three studies (n = 126) and increased by 1.8–1.92 kg in two studies (P = 0.02 and 0.003, respectively; n = 48). Pioglitazone was associated with increased peripheral insulin sensitivity (+23%–72%, standardized mean difference of 0.97 from trial start point to end point [95% CI, 0.36–1.58; n = 213]). Treatment reduced intramuscular tumor necrosis factor‐α (TNF‐α) levels (−30%; P = 0.02; n = 29), with mixed effects on serum TNF‐α and intramyocellular lipid concentrations. Treatment increased intramuscular markers of adenosine triphosphate (ATP) biosynthesis (ATP5A [+33%, P ≤ 0.05], ETFA [+60%, P ≤ 0.05], and CX6B1 [+ 33%, P = 0.01] [n = 24]), PGC1α and PGC1β messenger RNA expression (P < 0.05; n = 26), and AMPK phosphorylation (+38%, P < 0.05; n = 26). These data have low‐quality evidence profiles owing to risk of bias.Conclusions: Pioglitazone therapy increases skeletal muscle insulin sensitivity and can decrease intramuscular inflammation.
- 15 February 2023
- Published by Institute of Navigation
- p. 165-178
Development and Performance of a Digital Rubidium Atomic Frequency Standard (DRAFS) as a Next-Generation Space Clock
As increasing reliance on space-borne atomic clocks for position, navigation, and timing manifests, emphasis on pursuing higher performance clocks with robustness and longevity is tantamount. In this vein, key aspects for any space-borne atomic clock not only include excellent frequency stability, but must also be robust enough to survive the harsh environment of space. In this presentation, Frequency Electronics, Inc. (FEI) will present its innovative Digital Rubidium Atomic Frequency Standard (DRAFS) which has recently passed qualification testing. One engineering qualification unit has been fabricated thus far as well as two engineering design units which are reserved for additional testing. The focus in the presentation will be on the development of DRAFS as well as clock frequency stability while subjected to the environmental conditions the unit will experience in a space environment. Topics to be discussed include size, weight, power consumption, environmental sensitivity testing, frequency retrace, radiation hardening, and guaranteed lifetime of the unit over a projected twenty year period.
- 15 February 2023
- Published by Institute of Navigation
- p. 165-178
Development and Performance of a Digital Rubidium Atomic Frequency Standard (DRAFS) as a Next-Generation Space Clock
As increasing reliance on space-borne atomic clocks for position, navigation, and timing manifests, emphasis on pursuing higher performance clocks with robustness and longevity is tantamount. In this vein, key aspects for any space-borne atomic clock not only include excellent frequency stability, but must also be robust enough to survive the harsh environment of space. In this presentation, Frequency Electronics, Inc. (FEI) will present its innovative Digital Rubidium Atomic Frequency Standard (DRAFS) which has recently passed qualification testing. One engineering qualification unit has been fabricated thus far as well as two engineering design units which are reserved for additional testing. The focus in the presentation will be on the development of DRAFS as well as clock frequency stability while subjected to the environmental conditions the unit will experience in a space environment. Topics to be discussed include size, weight, power consumption, environmental sensitivity testing, frequency retrace, radiation hardening, and guaranteed lifetime of the unit over a projected twenty year period.
- Open Access
Pioglitazone for optimisation of clinical nutrition therapy in the critically ill patient: A Systematic Review
Background: Skeletal muscle wasting is a major determinant of physical functional disability in critical illness survivors, and contributes to post-intensive care syndrome. As yet, no therapies exist to address this major public health issue. Intramuscular bioenergetic failure and inflammation are understood to be the underpinning mechanisms, and carbohydrate and lipid oxidation are impaired. This systematic review synthesises the evidence that peroxisome proliferator-activated receptor gamma agonists may be a therapeutic option to optimise clinical nutrition in critically ill patients. Method: Systematic review and meta-analysis. Results: Fourteen studies over 19 publications were included. Lean body mass was unaffected (n=174). Pioglitazone treatment resulted in periperal insulin sensitivity increasing 30-71% (Standardised mean change 0.97 (95%CI 0.36-1.58; n=213). Intramuscular Tumour Necrosis Factor Alpha concentrations decreased in treatement arms (n=29) as did circulating interlukin-6 and Tumour Necrosis Factor Alpha (n=53). Intramyocellular Lipid concentrations decreased by 34-40% with pioglitazone therapy (n=60). Treatment increased intramuscular markers of Oxidative Phosphorylation (n=55), mitochondrial biogenesis(PGC1α and PGC1β; n=26) and β-oxidation (n=29) Conclusions: Pioglitazone therapy increases skeletal muscle insulin sensitivity, decreases intramyocellular lipid accumulation and systemic and intramuscular inflammation. Where lean body mass was measured, this was seen to increase. Pioglitazone may be an adjunctive therapy to optimise clinical nutrition in acutely unwell patients. Clinical relevancy statement: Pioglitazone may optimise clinical nutrition therapy in critically ill patients by normalising carbohydrate and lipid metabolism.
Open AccessPioglitazone for optimisation of clinical nutrition therapy in the critically ill patient: A Systematic Review
Background: Skeletal muscle wasting is a major determinant of physical functional disability in critical illness survivors, and contributes to post-intensive care syndrome. As yet, no therapies exist to address this major public health issue. Intramuscular bioenergetic failure and inflammation are understood to be the underpinning mechanisms, and carbohydrate and lipid oxidation are impaired. This systematic review synthesises the evidence that peroxisome proliferator-activated receptor gamma agonists may be a therapeutic option to optimise clinical nutrition in critically ill patients. Method: Systematic review and meta-analysis. Results: Fourteen studies over 19 publications were included. Lean body mass was unaffected (n=174). Pioglitazone treatment resulted in periperal insulin sensitivity increasing 30-71% (Standardised mean change 0.97 (95%CI 0.36-1.58; n=213). Intramuscular Tumour Necrosis Factor Alpha concentrations decreased in treatement arms (n=29) as did circulating interlukin-6 and Tumour Necrosis Factor Alpha (n=53). Intramyocellular Lipid concentrations decreased by 34-40% with pioglitazone therapy (n=60). Treatment increased intramuscular markers of Oxidative Phosphorylation (n=55), mitochondrial biogenesis(PGC1α and PGC1β; n=26) and β-oxidation (n=29) Conclusions: Pioglitazone therapy increases skeletal muscle insulin sensitivity, decreases intramyocellular lipid accumulation and systemic and intramuscular inflammation. Where lean body mass was measured, this was seen to increase. Pioglitazone may be an adjunctive therapy to optimise clinical nutrition in acutely unwell patients. Clinical relevancy statement: Pioglitazone may optimise clinical nutrition therapy in critically ill patients by normalising carbohydrate and lipid metabolism.
- 1 January 1997
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 4, 503-509 vol.4
Unique environmental test requirements for atomic frequency standards for space applications
Unique tests and considerations are required for the space qualification of atomic frequency standards (AFS). AFSs have several advantages (i.e., low drift rate and inherent insensitivity to radiation) over more conventional crystal oscillators, which make them preferred for specialized space applications. These features allow the users to obtain more precision in navigation, timing and for autonomous operation. AFSs are exposed to the usual battery of qualification tests normally prescribed for other flight hardware, but their responses to these environments may be unique. There are several additional tests, not applicable to most electronic hardware, that are required for AFS. These test environments are described and applied to the most desired capability of AFS: frequency stability.
- 1 January 1997
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 4, 503-509 vol.4
Unique environmental test requirements for atomic frequency standards for space applications
Unique tests and considerations are required for the space qualification of atomic frequency standards (AFS). AFSs have several advantages (i.e., low drift rate and inherent insensitivity to radiation) over more conventional crystal oscillators, which make them preferred for specialized space applications. These features allow the users to obtain more precision in navigation, timing and for autonomous operation. AFSs are exposed to the usual battery of qualification tests normally prescribed for other flight hardware, but their responses to these environments may be unique. There are several additional tests, not applicable to most electronic hardware, that are required for AFS. These test environments are described and applied to the most desired capability of AFS: frequency stability.